Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Expression Analysis and Mutational Status of Histone Methyltransferase KMT2D at Different Upper Tract Urothelial Carcinoma Locations

E. Laukhtina, U. Lemberger, A. Bruchbacher, D. Ilijazi, S. Korn, F. Berndl, D. D'Andrea, M. Susani, D. Enikeev, E. Compérat, SF. Shariat, MR. Hassler

. 2021 ; 11 (11) : . [pub] 20211104

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22001375

The gene coding for histone methyltransferase KMT2D is found among the top mutated genes in upper tract urothelial carcinoma (UTUC); however, there is a lack of data regarding its association with clinicopathologic features as well as survival outcomes. Therefore, we aimed to investigate KMT2D expression, mutation patterns, and their utility as prognostic biomarkers in patients with UTUC. A single-center study was conducted on tumor specimens from 51 patients treated with radical nephroureterectomy (RNU). Analysis of KMT2D protein expression was performed using immunohistochemistry (IHC). Customized next-generation sequencing (NGS) was used to assess alterations in KMT2D exons. Cox regression was used to assess the relationship of KMT2D protein expression and mutational status with survival outcomes. KMT2D expression was increased in patients with a previous history of bladder cancer (25% vs. 0%, p = 0.02). The NGS analysis of KMT2D exons in 27 UTUC tumors revealed a significant association between pathogenic KMT2D variants and tumor location (p = 0.02). Pathogenic KMT2D variants were predominantly found in patients with non-pelvic or multifocal tumors (60% vs. 14%), while the majority of patients with a pelvic tumor location (81% vs. 20%) did not harbor pathogenic KMT2D alterations. Both IHC and NGS analyses of KMT2D failed to detect a statistically significant association between KMT2D protein or KMT2D gene alteration status and clinical variables such as stage/grade of the disease or survival outcomes (all p > 0.05). KMT2D alterations and protein expression were associated with UTUC features such as multifocality, ureteral location, and previous bladder cancer. While KMT2D protein expression and KMT2D mutational status do not seem to have prognostic value in UTUC, they appear to add information to improve clinical decision-making regarding the type of therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22001375
003      
CZ-PrNML
005      
20220112153556.0
007      
ta
008      
220107s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jpm11111147 $2 doi
035    __
$a (PubMed)34834500
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia
245    10
$a Expression Analysis and Mutational Status of Histone Methyltransferase KMT2D at Different Upper Tract Urothelial Carcinoma Locations / $c E. Laukhtina, U. Lemberger, A. Bruchbacher, D. Ilijazi, S. Korn, F. Berndl, D. D'Andrea, M. Susani, D. Enikeev, E. Compérat, SF. Shariat, MR. Hassler
520    9_
$a The gene coding for histone methyltransferase KMT2D is found among the top mutated genes in upper tract urothelial carcinoma (UTUC); however, there is a lack of data regarding its association with clinicopathologic features as well as survival outcomes. Therefore, we aimed to investigate KMT2D expression, mutation patterns, and their utility as prognostic biomarkers in patients with UTUC. A single-center study was conducted on tumor specimens from 51 patients treated with radical nephroureterectomy (RNU). Analysis of KMT2D protein expression was performed using immunohistochemistry (IHC). Customized next-generation sequencing (NGS) was used to assess alterations in KMT2D exons. Cox regression was used to assess the relationship of KMT2D protein expression and mutational status with survival outcomes. KMT2D expression was increased in patients with a previous history of bladder cancer (25% vs. 0%, p = 0.02). The NGS analysis of KMT2D exons in 27 UTUC tumors revealed a significant association between pathogenic KMT2D variants and tumor location (p = 0.02). Pathogenic KMT2D variants were predominantly found in patients with non-pelvic or multifocal tumors (60% vs. 14%), while the majority of patients with a pelvic tumor location (81% vs. 20%) did not harbor pathogenic KMT2D alterations. Both IHC and NGS analyses of KMT2D failed to detect a statistically significant association between KMT2D protein or KMT2D gene alteration status and clinical variables such as stage/grade of the disease or survival outcomes (all p > 0.05). KMT2D alterations and protein expression were associated with UTUC features such as multifocality, ureteral location, and previous bladder cancer. While KMT2D protein expression and KMT2D mutational status do not seem to have prognostic value in UTUC, they appear to add information to improve clinical decision-making regarding the type of therapy.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lemberger, Ursula $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Bruchbacher, Andreas $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Ilijazi, Dafina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Korn, Stephan $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Berndl, Florian $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a D'Andrea, David $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Susani, Martin $u Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Enikeev, Dmitry $u Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia
700    1_
$a Compérat, Eva $u Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia $u Karl Landsteiner Institute of Urology and Andrology, 1010 Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, NY 10065, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX 75390, USA $u Department of Urology, Second Faculty of Medicine, Charles University, 150 06 Prague, Czech Republic
700    1_
$a Hassler, Melanie R $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria
773    0_
$w MED00203320 $t Journal of personalized medicine $x 2075-4426 $g Roč. 11, č. 11 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34834500 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220107 $b ABA008
991    __
$a 20220112153552 $b ABA008
999    __
$a ind $b bmc $g 1745456 $s 1152522
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 11 $e 20211104 $i 2075-4426 $m Journal of personalized medicine $n J. pers. med. $x MED00203320
LZP    __
$a Pubmed-20220107
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace